Pascal Schweizer
CEO/CFO and Co-Founder
Thermosome
Thermosome is developing targeted tumor therapies that utilize a proprietary TSL-based drug delivery technology to enhance local drug concentrations in cancer treatment. This approach aims to improve clinical efficacy for patients with locally advanced soft tissue sarcoma.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$5.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Locally advanced soft tissue sarcoma presents a significant challenge due to the difficulty in achieving sufficient drug concentrations at the tumor site, which limits the effectiveness of systemic chemotherapy and targeted therapies. This can lead to suboptimal treatment outcomes and increased risk of recurrence.
Solution
Thermosome is developing a targeted tumor therapy that utilizes a proprietary TSL-based drug delivery technology to enhance local drug concentrations within the tumor microenvironment. This approach aims to improve the therapeutic efficacy of cancer treatments, specifically for patients with locally advanced soft tissue sarcoma. By increasing the concentration of the drug directly at the tumor site, Thermosome's technology seeks to overcome the limitations of conventional systemic drug delivery, potentially leading to better clinical outcomes and reduced side effects. The company's lead compound, THE001, is currently in Phase I clinical trials.
Target Audience
The primary target audience includes patients with locally advanced soft tissue sarcoma and the oncologists treating them.
Features
- TSL-based drug delivery system for targeted tumor therapy
- Enhanced local drug concentrations at the tumor site
- Focus on improving treatment efficacy for locally advanced soft tissue sarcoma
- Lead compound THE001 in Phase I clinical trials